Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors.

abstract：:Lung cancer is the leading cause of cancer death in the United States. Despite evidence of molecular abnormalities in biological specimens, progress in this disease is hampered by the lack of diagnostic markers useful for clinical practice. The majority of patients with lung cancer are still diagnosed at an advanced s...

journal_title：Seminars in oncology

authors： Wardwell NR,Massion PP

更新日期：2005-06-01 00:00:00

abstract：:The epipodophyllotoxins, etoposide and teniposide, have been used in leukemias and malignant lymphomas for the past 15 years. Although etoposide has acquired a place in many first-line protocols for lymphomas and, more recently, for leukemias, the role of teniposide has remained limited. Teniposide is a more potent in...

journal_title：Seminars in oncology

authors： Sonneveld P

更新日期：1992-04-01 00:00:00

abstract：:The treatment for patients with unknown primary carcinoma, particularly those with unfavorable prognosis factors, has changed in the last decade, and continues to evolve. Empiric chemotherapy trials reported since 2000 with the newer drugs have improved the overall survival compared to retrospective historical data an...

journal_title：Seminars in oncology

authors： Greco FA,Pavlidis N

更新日期：2009-02-01 00:00:00

abstract：:Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term su...

journal_title：Seminars in oncology

authors： Laport GF,Williams SF

更新日期：1998-08-01 00:00:00

abstract：:90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a promising treatment option in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients wit...

journal_title：Seminars in oncology

authors： Gordon LI

更新日期：2003-12-01 00:00:00

abstract：:From 1975 to the mid 1990s, the incidence of cancer in the oral cavity and pharynx (OC/P) declined substantively, in large part because of successful educational and medical campaigns to reduce cigarette smoking and tobacco chewing. Recent data, however, suggest that the incidence trend in young adults has reversed. T...

journal_title：Seminars in oncology

authors： Bleyer A

更新日期：2009-10-01 00:00:00

abstract：:Successful allogeneic hematopoietic stem cell transplantation (HSCT) and solid organ transplantation require development of a degree of immune tolerance against allogeneic antigens. T lymphocytes play a critical role in allograft rejection, graft failure, and graft-versus-host disease (GVHD). T-cell tolerance occurs b...

journal_title：Seminars in oncology

authors： Alpdogan O,van den Brink MR

更新日期：2012-12-01 00:00:00

abstract：:Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin production in pathologic states such as inflammatory processes and cancer. The enzyme is often overexpressed in premalignant lesions and various cancers, including cancer of the lung. Inhibition of this enzyme with selective COX-2 inhibitors was found to ...

journal_title：Seminars in oncology

authors： Komaki R,Liao Z,Milas L

更新日期：2004-02-01 00:00:00

abstract：:Solid organ tumors associated with neoangiogenesis, as measured by increased microvessel density (MVD), have poorer prognoses. A similar observation of increased MVD has been made in hematologic malignancies; however, its prognostic significance remains unknown. We investigated changes in MVD in 122 newly diagnosed mu...

journal_title：Seminars in oncology

authors： Munshi NC,Wilson C

更新日期：2001-12-01 00:00:00

abstract：:The purpose of this review is to demonstrate a successful use of preclinical models of bladder cancer to confirm the therapeutic potential of new promising drug candidates. The bladder has long been thought to be an ideal target for investigating therapies. When developing a new antineoplastic pharmaceutical agent, th...

journal_title：Seminars in oncology

authors： Amit D,Gofrit ON,Matouk I,Birman T,Hochberg A

更新日期：2012-10-01 00:00:00

abstract：:Adjuvant chemotherapy in breast cancer has clearly been shown to reduce mortality. The benefits extend to pre- and postmenopausal women and those with node-negative, node-positive, estrogen receptor (ER)-positive, and ER-negative disease. Updated data regarding chemoendocrine therapy in postmenopausal women and anthra...

journal_title：Seminars in oncology

authors： Tan AR,Swain SM

更新日期：2001-08-01 00:00:00

abstract：:Pain is a common, feared, but treatable component of malignancy. The ability, however, to successfully relieve the difficult symptoms of progressive disease, including pain, require an understanding of tumor behavior, complications, and cancer therapy. Despite the treatability of cancer pain and multiple clinical opti...

journal_title：Seminars in oncology

authors： Brescia FJ

更新日期：1993-04-01 00:00:00

abstract：:Based on rigorous interpretation of current evidence, systemic therapy has two roles in the management of carcinoma of the uterine cervix. In patients with advanced or recurrent disease, single-agent chemotherapy constitutes the treatment of choice. The most extensively studied agents are the platinum compounds. Eithe...

journal_title：Seminars in oncology

authors： Thigpen T,Vance RB,Khansur T

更新日期：1994-04-01 00:00:00

abstract：:One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activates multiple signaling cascades that promote carcinogenesis and immune evasion. Therefore, these molecules have been extensively targeted in cancer immunotherapy. Beyond EGFR signaling cascade inhibition, some of these agen...

journal_title：Seminars in oncology

authors： Mazorra Z,Chao L,Lavastida A,Sanchez B,Ramos M,Iznaga N,Crombet T

更新日期：2018-01-01 00:00:00

abstract：:At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity--testicular cancer and smal...

journal_title：Seminars in oncology

authors： Loehrer PJ,Williams SD,Nichols CR,Einhorn LH

更新日期：1992-02-01 00:00:00

abstract：:Thus far the development of adjuvant therapies in melanoma has suffered greatly from the lack of effective drugs in stage IV melanoma. Chemotherapy, cytokines, vaccines, and combinations of drugs have been used with minimal success. This has led to adjuvant therapies that are not used uniformly or widely because of th...

journal_title：Seminars in oncology

authors： Eggermont AM,Testori A,Maio M,Robert C

更新日期：2010-10-01 00:00:00

abstract：:Maintenance therapy using rituximab is currently under consideration as a means of prolonging remission in patients with indolent non-Hodgkin's lymphoma. A phase II trial using rituximab as first-line therapy followed by maintenance treatment was carried out in patients with previously untreated indolent non-Hodgkin's...

journal_title：Seminars in oncology

authors： Hainsworth JD

更新日期：2004-02-01 00:00:00

abstract：:Phase I trials of the intraperitoneal (IP) administration of cisplatin have demonstrated that the drug can be safely delivered by this route with a major increase in exposure (approximately tenfold to 15-fold) of the cavity to the cytotoxic agent compared with that of the systemic circulation. Phase I trials of IP cis...

journal_title：Seminars in oncology

authors： Markman M

更新日期：1989-08-01 00:00:00

abstract：:Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rate...

journal_title：Seminars in oncology

authors： Carney DN,Grogan L,Smit EF,Harford P,Berendsen HH,Postmus PE

更新日期：1990-02-01 00:00:00

abstract：:Sentinel nodes (SNs) are the first set of nodes to receive drainage and cancer cells from a primary tumor. While there may be a single SN, frequently there are one to three or more SNs. The development of sentinel node surgery over the last decade has led to dramatic changes in the surgical approach to regional nodes ...

journal_title：Seminars in oncology

authors： Krag DN,Weaver DL

更新日期：2002-06-01 00:00:00

abstract：:Selective aromatase inhibitors cause regression of breast carcinomas by reducing estrogen production via inhibition of the enzyme aromatase (estrogen synthetase). A higher incidence of hormone-dependent breast cancer occurs in postmenopausal women than in younger women. Thus, total estrogen blockade is more likely to ...

journal_title：Seminars in oncology

authors： Brodie AM,Njar VC

更新日期：1996-08-01 00:00:00

abstract：:Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise revi...

journal_title：Seminars in oncology

authors： Caruana I,Diaconu I,Dotti G

更新日期：2014-10-01 00:00:00

abstract：:Colorectal cancer (CRC) is a common malignancy in the elderly. Randomized trials have demonstrated that adjuvant and palliative chemotherapy for CRC improves survival and quality of life. Unfortunately, there is a lack of evidence-based data about elderly patients to guide decisions regarding therapy. Clinical trials ...

journal_title：Seminars in oncology

authors： Raftery L,Sanoff HK,Goldberg R

更新日期：2008-12-01 00:00:00

abstract：:Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma. In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies. Therefore, randomized phase III studies have b...

journal_title：Seminars in oncology

authors： Hiddemann W,Dreyling M,Unterhalt M

更新日期：2003-02-01 00:00:00

abstract：:Transitional cell carcinoma of the urothelium is a highly chemosensitive tumor. Combination chemotherapy can provide both palliation and a modest survival advantage in patients with advanced disease. As shown in a recent phase III trial, the new gold standard should be considered gemcitabine/cisplatin, although toxici...

journal_title：Seminars in oncology

authors： Carles J,Nogué M

更新日期：2001-06-01 00:00:00

abstract：:Data from various phase I/II studies of carboplatin in combination with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) have suggested that the degree of thrombocytopenia seen is less than that expected when carboplatin is given alone. However, some studies also have suggested that the area under the p...

journal_title：Seminars in oncology

authors： Calvert AH,Boddy A,Bailey NP,Siddiqui N,Humphreys A,Hughes A,Robson L,Gumbrell L,Thomas H,Chapman F

更新日期：1995-10-01 00:00:00

abstract：:Although bone and soft tissue sarcomas are not common, a significant number of patients who develop these tumors will die with metastatic disease. Part of the reason is that many of the patients have advanced disease at diagnosis. Identification of an etiologic agent should allow for diagnosis at an earlier stage. Thi...

journal_title：Seminars in oncology

authors： McClay EF

更新日期：1989-08-01 00:00:00

abstract：:Treatment of hormone-refractory prostate cancer (HRPC) historically has shown limited efficacy. However, taxane-based chemotherapy regimens recently have demonstrated more promising results. Several groups have reported significant efficacy and minimal toxicity in patients with hormone-refractory disease receiving est...

journal_title：Seminars in oncology

authors： Oh WK,Kantoff PW

更新日期：1999-10-01 00:00:00

abstract：:Based on the results of several small clinical studies, the experimental data of J. T. Isaacs, and the theoretical considerations about the heterogeneity of prostatic cancer, we investigated the effect of simultaneous hormone-chemotherapy in previously untreated advanced prostatic cancer. Patients (n = 145; 117 stage ...

journal_title：Seminars in oncology

authors： Pummer K

更新日期：1991-10-01 00:00:00

abstract：:The efficacy and toxicity of combination intravenous carboplatin (300 mg/m2) and cyclophosphamide (600 mg/m2) were evaluated in 70 newly diagnosed patients with advanced-stage epithelial ovarian cancer. Cycles were administered at 4-week intervals for a total of six cycles, and treatment was provided on an outpatient ...

journal_title：Seminars in oncology

authors： Teeling M,Hayes Y,Fitzmaurice B,McGing P,Carney DN

更新日期：1992-02-01 00:00:00